Table 1.

Drug summary.

Generic drug name	Panobinostat
Market name (pharmaceutical company)	Farydac® (Novartis)
Phase	Approved
Indication	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent
Pharmacology description/mechanism of action	HDAC inhibitor
Route of administration	Oral
Chemical structure	2-Hydroxypropanoic acid, compound with 2-(E)-N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide [1 : 1]
Pivotal trial (s)	Panorama 1
Metabolism and elimination	Extensively metabolized, eliminated equally through the kidney and liver
Main toxicities	Thrombocytopenia, anemia, neutropenia, diarrhea, fatigue